Thank you - and yes it was due to the pricing construct for both, so thanks for explaining it.
(also acknowledge common is probably more appropriate way to label it than me saying 'mainstream')
but I wonder, if it makes more sense commercially, there's nothing stopping them from pivoting from rare to common down the line right - or would there be? Obviously not great for sufferes of the rare diseases
with regards to patents, do these apply to the drug itself or the drug being used for a particular disorder?
eg could a strategy be... to focus on the rare diseases for now (perhaps an easier pathway to commercialisation) and then prove out common disorders in the background, to launch when parents expire on Retts, PHS, PMD etc
Or is this still thinking and doesn't really work?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)